Innoviva (INVA) Debt Ratio (2010 - 2026)
Innoviva posted quarterly Debt Ratio of 0.14 for Q1 2026, down 60.73% year-on-year from 0.36 in Q1 2025, and down 10.84% on a QoQ basis from 0.16 in Q4 2025.
Innoviva (INVA) has 17 years of Debt Ratio data on file, last reported at 0.14 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio fell 60.73% year-over-year to 0.14; the trailing twelve-month figure through Mar 2026 stood at 0.14 (down 60.73% YoY), and the FY2025 full-year result was 0.16, down 54.26% from the prior year.
- Debt Ratio for Q1 2026 stood at 0.14, down from 0.16 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.44 in Q4 2022 and bottomed at 0.08 in Q2 2022.
- The 5-year median for Debt Ratio is 0.36 (2025), against an average of 0.3.
- The widest annual swing landed in 2022, when Debt Ratio slumped 82.91%; it then jumped 371.44% in 2023.
- A 5-year view of Debt Ratio shows it stood at 0.44 in 2022, then slipped by 18.22% to 0.36 in 2023, then fell by 3.97% to 0.34 in 2024, then slumped by 54.26% to 0.16 in 2025, then retreated by 10.84% to 0.14 in 2026.
- The last three Debt Ratio figures came in at 0.14 (Q1 2026), 0.16 (Q4 2025), and 0.18 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 0.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.14 |
| Dec 31, 2025 | 0.16 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | 0.34 |
| Mar 31, 2025 | 0.36 |
| Dec 31, 2024 | 0.34 |
| Sep 30, 2024 | 0.36 |
| Jun 30, 2024 | 0.37 |
| Mar 31, 2024 | 0.35 |
| Dec 31, 2023 | 0.36 |
| Sep 30, 2023 | 0.38 |
| Jun 30, 2023 | 0.40 |
| Mar 31, 2023 | 0.39 |
| Dec 31, 2022 | 0.44 |
| Sep 30, 2022 | 0.41 |
| Jun 30, 2022 | 0.08 |
| Mar 31, 2022 | 0.09 |
| Dec 31, 2021 | 0.43 |
| Sep 30, 2021 | 0.44 |
| Jun 30, 2021 | 0.49 |
| Mar 31, 2021 | 0.36 |
| Dec 31, 2020 | 0.39 |
| Sep 30, 2020 | 0.42 |
| Jun 30, 2020 | 0.43 |
| Mar 31, 2020 | 0.48 |
| Dec 31, 2019 | 0.52 |
| Sep 30, 2019 | 0.57 |
| Jun 30, 2019 | 0.60 |
| Mar 31, 2019 | 0.65 |
| Dec 31, 2018 | 0.70 |
| Sep 30, 2018 | 1.37 |
| Jun 30, 2018 | 1.44 |
| Mar 31, 2018 | 1.75 |
| Dec 31, 2017 | 1.63 |
| Sep 30, 2017 | 1.54 |
| Jun 30, 2017 | 1.12 |
| Mar 31, 2017 | 1.20 |
| Dec 31, 2016 | 1.89 |
| Sep 30, 2016 | 1.30 |
| Jun 30, 2016 | 1.28 |
| Mar 31, 2016 | 1.25 |
| Dec 31, 2015 | 1.18 |
| Sep 30, 2015 | 1.12 |
| Jun 30, 2015 | 1.05 |
| Mar 31, 2015 | 0.98 |
| Dec 31, 2014 | 0.90 |
| Sep 30, 2014 | 0.83 |
| Jun 30, 2014 | 0.74 |
| Dec 31, 2013 | 0.06 |
| Mar 31, 2012 | 0.00 |
| Dec 31, 2011 | 0.00 |
| Sep 30, 2011 | 0.00 |
| Jun 30, 2011 | 0.00 |
| Dec 31, 2010 | 0.00 |